Therapeutics Discovery scientists at MD Anderson are developing a targeted therapy against the epigenetic regulator protein CBP/p300, which is responsible for cancer development in patients with early onset acute myeloid leukemia and diffuse large B cell lymphoma.

Authors

• Person: Not available Organization: MD Anderson Cancer Center
  How Therapeutics Discovery is developing targeted therapies for ...

Sources

• How Therapeutics Discovery is developing targeted therapies for ... www.mdanderson.org MD Anderson Cancer Center via serper

Referenced by nodes (1)

• UT MD Anderson Cancer Center entity